Retatrutide (30mg)

Retatrutide (30mg)

$279.99
$279.99
SAVE Sold out

✔ Verified 99+% Purity

✔ Third-Party Approved & Tested

✔ Fast Australian Shipping

Research Use Only

This product is sold for research purposes only. It is not intended for human or animal consumption. By purchasing this product, you confirm that you are a qualified researcher or are purchasing for legitimate research purposes.

Bacteriostatic Water (20mg)
Add Bacteriostatic Water (20mg)
Required for reconstitution
$24.99
Retatrutide (30mg)

Retatrutide (30mg)

$279.99
$279.99
SAVE Sold out

Shipping Information

Orders are processed and dispatched within 24 hours of payment confirmation (Monday–Friday). Delivery typically arrives within 1–4 business days via Standard post, and 1-2 business days via Express post.

View full details

Retatrutide

Supplied as a lyophilized (freeze-dried) white powder in a sealed sterile vial. Requires reconstitution with bacteriostatic water prior to use. Each vial contains 30mg of Retatrutide at ≥99% purity.

Retatrutide (LY3437943) is a single 39 amino acid peptide acting as a triple receptor agonist at the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It is built on a GIP peptide backbone carrying non-coded residues at positions 2, 13, and 20, with a C20 fatty diacid conjugated through a gamma-Glu-AEEA linker to extend its half-life. This triagonist design combines incretin-receptor activity with glucagon-receptor signalling, and it has been extensively researched for its effects on fat loss, appetite regulation, metabolic markers, and energy expenditure — making it one of the most closely studied next-generation peptides in metabolic research.

Research Background

Research has investigated Retatrutide's effects on energy homeostasis, glucose handling, lipid profiles, and hepatic lipid content in preclinical metabolic models. As a triple agonist, it is frequently studied comparatively against dual-agonist and single-target compounds such as semaglutide and tirzepatide, to characterise how combined GLP-1, GIP, and glucagon receptor activation influences fat metabolism and energy expenditure differently from incretin-only mechanisms. Its extended half-life, achieved through fatty-acid conjugation, has also made it a useful tool for studying sustained receptor engagement in longitudinal metabolic research protocols.

Key Research Areas
Fat loss research, including visceral adiposity
Appetite regulation — reduced food intake and caloric studies
Metabolic markers — blood pressure, lipids, waist circumference
Energy expenditure via glucagon receptor activation
Comparative research alongside semaglutide and tirzepatide
Studied Mechanisms
Triple agonism at GLP-1, GIP, and glucagon receptors
C20 fatty diacid conjugation via gamma-Glu-AEEA linker for extended half-life
Regulation of energy homeostasis and glucose handling
Modulation of lipid profiles and hepatic lipid content
Non-coded residue substitutions supporting receptor selectivity

Product Specifications

Molecular FormulaC₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight4,731.4 g/mol
CAS Number2381089-83-2
Sequence39 amino acid peptide on a GIP backbone with non-coded residues at positions 2, 13 & 20; C20 fatty diacid conjugated via a gamma-Glu-AEEA linker
AppearanceWhite/off-white Lyophilised Powder
Purity≥99.3% (HPLC Verified)
StorageStore at -20°C, away from light and moisture
Research Use Only

This product is strictly intended for in vitro laboratory research purposes only. It is not approved for human or veterinary use, and is not intended for consumption, injection, or any therapeutic application.